Want to see TENX full AI Analyst Report?
Tenax Therapeutics (TENX) Stock Statistics & Valuation Metrics
Total Valuation
Tenax Therapeutics has a market cap or net worth of $67.74M. The enterprise value is $622.17M.
- Market Cap
- $67.74M
- Enterprise Value
- $622.17M
Share Statistics
Tenax Therapeutics has 37,423,916 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 37,423,916
- Owned by Insiders
- 20.22%
- Owned by Institutions
- 20.53%
Financial Efficiency
Tenax Therapeutics’s return on equity (ROE) is -0.54 and return on invested capital (ROIC) is -58.09%.
- Return on Equity (ROE)
- -0.54
- Return on Assets (ROA)
- -0.50
- Return on Invested Capital (ROIC)
- -58.09%
- Return on Capital Employed (ROCE)
- -0.58
- Revenue Per Employee
- 0
- Profits Per Employee
- -3.51M
- Employee Count
- 15
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Tenax Therapeutics is -1.16. Tenax Therapeutics’s PEG ratio is 0.05.
- PE Ratio
- -1.16
- PS Ratio
- 0.00
- PB Ratio
- 0.80
- Price to FCF
- -0.88
- Price to Operating Cash Flow
- -1.77
- PEG Ratio
- 0.05
Income Statement
In the last 12 months, Tenax Therapeutics had revenue of 0 and earned -52.60M in profits. Earnings per share was -1.34.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -56.38M
- Pretax Income
- -52.60M
- Net Income
- -52.60M
- EBITDA
- -52.60M
- Earnings Per Share (EPS)
- -1.34
Cash Flow
In the last 12 months, operating cash flow was -49.35M and capital expenditures 0, giving a free cash flow of -49.35M billion.
- Operating Cash Flow
- -49.35M
- Free Cash Flow
- -49.35M
- Free Cash Flow per Share
- -0.92
Dividends & Yields
Tenax Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -106.13%
- Earnings Yield
- -75.25%
Stock Price Statistics
- Beta
- 0.58
- 52-Week Price Change
- -77.01%
- 50-Day Moving Average
- 1.84
- 200-Day Moving Average
- 9.84
- Relative Strength Index (RSI)
- 39.01
- Average Volume (3m)
- 5.65M
Important Dates
Tenax Therapeutics upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Tenax Therapeutics as a current ratio of 14.56, with Debt / Equity ratio of 0.00%
- Current Ratio
- 14.56
- Quick Ratio
- 14.56
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.85
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Tenax Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Tenax Therapeutics EV to EBITDA ratio is 1.41, with an EV/FCF ratio of 1.53.
- EV to Sales
- 0.00
- EV to EBITDA
- 1.41
- EV to Free Cash Flow
- 1.53
- EV to Operating Cash Flow
- 1.53
Balance Sheet
Tenax Therapeutics has $113.73M in cash and marketable securities with $0.00 in debt, giving a net cash position of $113.73M billion.
- Cash & Marketable Securities
- $113.73M
- Total Debt
- $0.00
- Net Cash
- $113.73M
- Net Cash Per Share
- $3.04
- Tangible Book Value Per Share
- $2.03
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Tenax Therapeutics is $9.63, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $9.63
- Price Target Upside
- 490.49% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 10
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -22.58%
Scores
- Smart Score
- 5
- AI Score
- 43
